↓ Skip to main content

Role of maspin in cancer

Overview of attention for article published in Clinical and Translational Medicine, March 2013
Altmetric Badge

Mentioned by

facebook
1 Facebook page

Citations

dimensions_citation
95 Dimensions

Readers on

mendeley
84 Mendeley
Title
Role of maspin in cancer
Published in
Clinical and Translational Medicine, March 2013
DOI 10.1186/2001-1326-2-8
Pubmed ID
Authors

Rossana Berardi, Francesca Morgese, Azzurra Onofri, Paola Mazzanti, Mirco Pistelli, Zelmira Ballatore, Agnese Savini, Mariagrazia De Lisa, Miriam Caramanti, Silvia Rinaldi, Silvia Pagliaretta, Matteo Santoni, Chiara Pierantoni, Stefano Cascinu

Abstract

Maspin (mammary serine protease inhibitor), is a member of the serine protease inhibitor/non-inhibitor superfamily. Its expression is down-regulated in breast, prostate, gastric and melanoma cancers but over-expressed in pancreatic, gallbladder, colorectal, and thyroid cancers suggesting that maspin may play different activities in different cell types. However, maspin expression seems to be correlated with better prognosis in prostate, bladder, lung, gastric, colorectal, head and neck, thyroid and melanoma cancer. In breast and ovarian cancer maspin significance is associated with its subcellular localization: nucleus maspin expression correlates with a good prognosis, whilst in pancreatic cancer it predicts a poor prognosis. Since tumor metastasis requires the detachment and invasion of tumor cells through the basement membrane and stroma, a selectively increased adhesion by the presence of maspin may contribute to the inhibition of tumor metastasis. Furthermore the different position of maspin inside the cell or its epigenetic modifications may explain the different behavior of the expression of maspin between tumors. The expression of maspin might be useful as a prognostic and possibly predictive factor for patients with particular types of cancer and data can guide physicians in selecting therapy. Its expression in circulating tumor cells especially in breast cancer, could be also useful in clinical practice along with other factors, such as age, comorbidities, blood examinations in order to select the best therapy to be carried out. Focusing on the malignancies in which maspin showed a positive prognostic value, therapeutic approaches studied so far aimed to re-activate a dormant tumor suppressor gene by designed transcription factors, to hit the system that inhibits the expression of maspin, to identify natural substances that can determine the activation and the expression of maspin or possible "molecules binds" to introduce maspin in cancer cell and gene therapy capable of up-regulating the maspin in an attempt to reduce primarily the risk of metastasis.Further studies in these directions are necessary to better define the therapeutic implication of maspin.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 84 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Iran, Islamic Republic of 1 1%
United States 1 1%
Poland 1 1%
South Africa 1 1%
Unknown 80 95%

Demographic breakdown

Readers by professional status Count As %
Student > Master 15 18%
Student > Ph. D. Student 14 17%
Researcher 12 14%
Student > Bachelor 11 13%
Student > Postgraduate 6 7%
Other 8 10%
Unknown 18 21%
Readers by discipline Count As %
Agricultural and Biological Sciences 21 25%
Medicine and Dentistry 19 23%
Biochemistry, Genetics and Molecular Biology 15 18%
Immunology and Microbiology 2 2%
Nursing and Health Professions 1 1%
Other 8 10%
Unknown 18 21%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 March 2013.
All research outputs
#22,758,309
of 25,373,627 outputs
Outputs from Clinical and Translational Medicine
#851
of 1,060 outputs
Outputs of similar age
#183,432
of 207,690 outputs
Outputs of similar age from Clinical and Translational Medicine
#4
of 5 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,060 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.2. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 207,690 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one.